All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
What advances have there been in biomarkers for AML?
During the 2021 ASCO Annual Meeting, the AML Hub spoke with Chris Hourigan, National Institutes of Health, Bethesda, US. We asked, What advances have there been in biomarkers for AML?
The use of whole-genome sequencing as an alternative diagnostic tool for cytogenetic analysis in myeloid cancers
The identification of genomic mutations by molecular analysis is vital to determine diagnosis, prognosis, and treatment in patients with...
"The AML Hub is a trusted, respected, and comprehensive resource where clinicians and researchers interested in AML can confidently learn about the most exciting and novel clinical and biological advances in the field."